Success Metrics

Clinical Success Rate
33.3%

Based on 2 completed trials

Completion Rate
33%(2/6)
Active Trials
0(0%)
Results Posted
250%(5 trials)
Terminated
4(67%)

Phase Distribution

Ph phase_2
1
17%
Ph phase_1
1
17%
Ph phase_3
4
67%

Phase Distribution

1

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
4(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

2 of 6 finished

Non-Completion Rate

66.7%

4 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(2)
Terminated(4)

Detailed Status

Terminated4
Completed2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
33.3%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (16.7%)
Phase 21 (16.7%)
Phase 34 (66.7%)

Trials by Status

terminated467%
completed233%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_3

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03

NCT03420781
terminatedphase_3

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04

NCT03383146
terminatedphase_3

Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02

NCT03426345
terminatedphase_3

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01

NCT03285308
completedphase_2

Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis

NCT02357420
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03420781Phase 3

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03

Terminated
NCT03383146Phase 3

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04

Terminated
NCT03426345Phase 3

Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02

Terminated
NCT03285308Phase 3

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01

Terminated
NCT02357420Phase 2

Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis

Completed
NCT02466711Phase 1

Effect of Relamorelin on Satiation, Gastric Volume, Gastric Accommodation and Distal Gastric Function in Healthy Volunteers

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6